CCNJ (Gene)

Organism:

Homo sapiens

Synonyms:CCNJ, ENTREZ:54619, HGNC:23434, NM_001134375, NM_001134376, NM_019084, NP_001127847, NP_001127848, NP_061957, XM_005269921, XM_011539885, XM_017016354, XM_017016355, XM_017016356, XP_005269978, XP_011538187, XP_016871843, XP_016871844, XP_016871845, bA690P14.1, cyclin J

Omim:OMIM:620395

Id:ENSG00000107443

Hgnc:HGNC:23434

Entrez:54619

Ensembl:ENSG00000107443

Description:cyclin J

Predicted to enable cyclin-dependent protein serine/threonine kinase regulator activity. Predicted to be involved in mitotic cell cycle phase transition and regulation of cyclin-dependent protein serine/threonine kinase activity. Predicted to be part of cyclin-dependent protein kinase holoenzyme complex. Predicted to be active in centrosome; cytoplasm; and nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CCNJ's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CCNJ.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CCNJ.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CCNJ.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CCNJ.

Results found

Linked to

	Label	Description
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 1 GLUTATHIONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE153867 olaparib 6 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 1 GLUTATHIONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE153867 olaparib 6 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.